Back to Search
Start Over
Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer
- Source :
- Breast Cancer Research and Treatment. 172:437-444
- Publication Year :
- 2018
- Publisher :
- Springer Science and Business Media LLC, 2018.
-
Abstract
- TP53 mutation is the most common mutation in breast cancer, and it is considered a target marker of triple-negative breast cancer (TNBC). We investigated whether expression of p53 detected by immunochemical staining predicts the chemotherapy response of TNBC. A total of 11,393 TNBC patients who had between stage I and stage III enrolled in the Korean Breast Cancer Society Registry database from January 1, 2000 to December 31, 2015. There were 6,331 ‘p53-positive (+) TNBC’ patients and 5062 ‘p53-negative (−) TNBC’ patients. In univariate analysis, p53(+) TNBC had a worse prognosis than p53(−) TNBC in patients not receiving chemotherapy (P = 0.003). However, there was no difference in prognosis between p53(+) TNBC and p53(−) TNBC for patients receiving chemotherapy. In multivariate analysis adjusted for age and stage, the risk of p53(+) TNBC was 1.84 times higher than that of p53(−) TNBC in the non-chemotherapy group. However, there was no difference between p53(+) TNBC and p53(−) TNBC in patients receiving chemotherapy. In p53(+) TNBC, the risk was 0.6-fold lower when chemotherapy was administered than when chemotherapy was not administered. However, in p53(−) TNBC, there was no risk reduction effect by chemotherapy. The prognosis of p53(+) TNBC has worse than p53(−) TNBC, but the risk for survival was significantly reduced with chemotherapy. It suggests that p53(+) TNBC would be more sensitive to chemotherapy than p53(−) TNBC.
- Subjects :
- Adult
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
medicine.medical_treatment
Triple Negative Breast Neoplasms
Disease-Free Survival
03 medical and health sciences
0302 clinical medicine
Breast cancer
Internal medicine
Biomarkers, Tumor
medicine
Humans
Stage (cooking)
P53 expression
Triple-negative breast cancer
Aged
Chemotherapy
Univariate analysis
business.industry
Immunochemical staining
Middle Aged
Prognosis
medicine.disease
030104 developmental biology
Chemotherapy, Adjuvant
030220 oncology & carcinogenesis
Mutation
Immunohistochemistry
Female
Tumor Suppressor Protein p53
business
Subjects
Details
- ISSN :
- 15737217 and 01676806
- Volume :
- 172
- Database :
- OpenAIRE
- Journal :
- Breast Cancer Research and Treatment
- Accession number :
- edsair.doi.dedup.....9df2821eec3c78bf01f4314e63eb9c8c